Preventive Effects of Ceftriaxone and Pregabalin on peripheral Neuropathy-Induced by Cisplatinin Mice

Peripheral neuropathy is one of the serious side effects of cisplatin that has limited its clinical use. Therefore, this study was designed to investigate the protective effects of pregabalin and ceftriaxone on cisplatin-induced peripheral neuropathy. Thirty-two swiss albino male mice were randomly divided into four equal groups including the control group, cisplatin, pregabalin, and ceftriaxone. Cisplatin (2 mg/kg) was given intraperitoneally twice a week for 6 times.

Pregabalin (30 mg/kg) and ceftriaxone (100 mg/kg) were administrated intraperitoneally once a day for the first seven days of the study, and 30 minutes before each injection of cisplatin. The tail-flick test was performed to evaluate cisplatin-induced peripheral neuropathy. The MDA and TAC levels were determined in the serum using colorimetric methods. Cisplatin meaningfully reduced the latency time in the tail-flick test as well as TAC in serum while increasing MDA. Treatment of mice with pregabalin or ceftriaxone significantly increased the pain threshold in the tail-flick test and inhibited cisplatin-induced changes in MDA and TAC. These results show that pregabalin and ceftriaxone effectively ameliorate CDDP-induced peripheral neuropathy.